Got The D?

Recognizing Glucose-6-Phosphate Dehydrogenase Deficiency (G6PDd) and Improving Outcomes in Newborns

This educational module is provided by the g6pd Deficiency Foundation

g6pd Deficiency Foundation

References

Neonatal Severe Hyperbilirubinemia

- Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF. Hyperbilirubinemia in the newborn infant > or =35 weeks' gestation: an update with clarifications. *Pediatrics*. 2009;124(4):1193–1198.

Hyperbilirubinemia Management

- American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. *Pediatrics*. 2004;114(1):297–316.

Hyperbilirubinemia Neurotoxicity

- Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF. Hyperbilirubinemia in the newborn infant > or =35 weeks' gestation: an update with clarifications. *Pediatrics*. 2009;124(4):1193–1198.

G6PD Deficiency Should Be Considered When…

- Frank JE. Diagnosis and management of G6PD deficiency. *Am Fam Physician*. 2005;72(7):1277–1282.
- *American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114(1):297–316.*

Epidemiology

- Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. *Lancet*. 2008;*371*(9606):64–74.
- Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. *Blood Cells Mol Dis*. 2009;*42*(3):267–278.
- Vidavalur R, Bhutani VK. Economic evaluation of point of care universal newborn screening for glucose-6-phosphate dehydrogenase deficiency in United States. *J Matern Fetal Neonatal Med*. Published online 2021:1–9.
- Oppenheim A, Jury CL, Rund D, Vulliamy TJ, Luzzatto L. G6PD Mediterranean accounts for the high prevalence of G6PD deficiency in Kurdish Jews. *Hum Genet*. 1993;91(3):293–294.
- Goo YK, Ji SY, Shin HI, et al. First evaluation of glucose-6-phosphate dehydrogenase (G6PD) deficiency in vivax malaria endemic regions in the Republic of Korea. *PLoS One*. 2014;9(5):e97390.
- Chinevere TD, Murray CK, Grant E Jr, Johnson GA, Duelm F, Hospenthal DR. Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army personnel. *Mil Med*. 2006;171(9):905–907.

References

Genetics

- Au W-Y, Lam V, Pang A, et al. Glucose-6-phosphate dehydrogenase deficiency in female octogenarians, nanogenarians, and centenarians. *J Gerontol A Biol Sci Med Sci*. 2006;61(10):1086–1089.

Biochemistry

- Source: (Kaplan M, Hammerman C, Bhutani VK. The preterm infant: A high-risk situation for neonatal hyperbilirubinemia due to glucose-6-phosphate dehydrogenase deficiency. *Clin Perinatol*. 2016;43(2):325–340.)

WHO Classification

- Glucose-6-phosphate dehydrogenase deficiency: WHO Working Group. *Bull World Health Organ*. 1989;67(6):601–611.
- Frank JE. Diagnosis and management of G6PD deficiency. *Am Fam Physician*. 2005;72(7):1277–1282.

Neonatal Presentation

- Johnson L, Bhutani VK, Karp K, Sivieri EM, Shapiro SM. Clinical report from the pilot USA Kernicterus Registry (1992 to 2004). *J Perinatol*. 2009;29 Suppl 1(S1):S25–S45.
- Kaplan M, Hammerman C, Vreman HJ, Stevenson Kaplan M, Algur N, Hammerman C. Onset of jaundice in glucose-6-phosphate dehydrogenase-deficient neonates. *Pediatrics*. 2001;*108*(4):956–959.
- Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group. Bull World Health Organ. 1989;67(6):601–611.
- Updating the WHO G6PD classification of variants and the International Classification of Diseases, 11th revision (ICD-11). *Malaria Policy Advisory Committee Meeting*. https://www.who.int/malaria/mpac/mpac-october2019-session7-updating-G6PD-classification.pdf.

Extreme Hyperbilirubinemia Effects, Acute and Chronic

- Newman TB, Maisels MJ. Evaluation and treatment of jaundice in the term newborn: a kinder, gentler approach. *Pediatrics*. 1992;89(5 Pt 1):809–818.
- Wusthoff CJ, Loe IM. Impact of bilirubin-induced neurologic dysfunction on neurodevelopmental outcomes. *Semin Fetal Neonatal Med*. 2015;20(1):52–57.

Kernicterus Spectrum Disorders

- Le Pichon JB, Riordan SM, Watchko J, Shapiro SM. The neurological sequelae of neonatal hyperbilirubinemia: definitions, diagnosis and treatment of the kernicterus spectrum disorders (KSDs). *Curr Pediatr Rev*. 2017;13(3):199–209.

References

BIND

- Koziol LF, Budding DE, Chidekel D. Hyperbilirubinemia: subcortical mechanisms of cognitive and behavioral dysfunction. *Pediatr Neurol*. 2013;48(1):3–13. https://pubmed.ncbi.nlm.nih.gov/23290014/
- Wusthoff CJ, Loe IM. Impact of bilirubin-induced neurologic dysfunction on neurodevelopmental outcomes. *Semin Fetal Neonatal Med*. 2015;20(1):52–57.
- Bhutani VK, Johnson-Hamerman L. The clinical syndrome of bilirubin-induced neurologic dysfunction. *Semin Fetal Neonatal Med*. 2015;20(1):6–13.
- Olds C, Oghalai JS. Audiologic impairment associated with bilirubin-induced neurologic damage. *Semin Fetal Neonatal Med*. 2015;20(1):42–46.

Adult Outcomes

- Hokkanen L, Launes J, Michelsson K. Adult neurobehavioral outcome of hyperbilirubinemia in full term neonates—a 30 year prospective follow-up study. *PeerJ*. 2014;2:e294.

American Academy of Pediatrics, Clinical Practice Guidelines Revised

- Kemp AR, Newman RB, Slaughter JL et al. **Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 04 more Weeks of Gestation**. American Academy of Pediatrics, Vol. 150, Issue 3. September 2022.

Hidden Risks

- MacDonald MG. Hidden risks: early discharge and bilirubin toxicity due to glucose 6-phosphate dehydrogenase deficiency. *Pediatrics*. 1995;96(4 Pt 1):734–738.

Hospital Screening, Current Recommendations

- WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. *Bull World Health Organ.* 1989;67(6):601–611.
- Kaplan M, Hammerman C, Bhutani VD. Parental education and the WHO neonatal G-6-PD screening program: a quarter century later. *J Perinatol.* 2015;35(10):779–784.

Hospital Screening, US and International

- Watchko JF, Kaplan M, Stark AR, Stevenson DK, Bhutani VK. Should we screen newborns for glucose-6-phosphate dehydrogenase deficiency in the United States? *J Perinatol*. 2013;33(7):499–504.

Florescent Spot Testing

- Cherepnalkovski AP, Marusic E, Piperkova K, et al. Influence of the inherited glucose-t-phosphate dehydrogenase deficiency on the appearance of neonatal hyperbilirubinemia in southern Croatia. *Acta Inform Med*. 2015;23(5):264–267.

References

Spectrophotometric Testing

- Cherepnalkovski AP, Marusic E, Piperkova K, et al. Influence of the inherited glucose-t-phosphate dehydrogenase deficiency on the appearance of neonatal hyperbilirubinemia in southern Croatia. *Acta Inform Med*. 2015;23(5):264–267.
- Kaplan M, Beutler E, Vreman HJ, et al. Neonatal hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient heterozygotes. *Pediatrics*. 1999;104(1):68–74.

Molecular Testing

- Watchko JF, Kaplan M, Stark AR, Stevenson DK, Bhutani VK. Should we screen newborns for glucose-6-phosphate dehydrogenase deficiency in the United States? *J Perinatol*. 2013;33(7):499-504.
- Nantakomol D, Paul R, Palasuwan A, Day NPJ, White NJ, Imwong M. Evaluation of the phenotypic test and genetic analysis in the detection of glucose-6-phosphate dehydrogenase deficiency. *Malar J.* 2013;12:239.

G6PD/6PGD Assay

- Miao J-K, Chen Q-X, Bao L-M, et al. Determination of optimal cutoff value to accurately identify glucose-6-phosphate dehydrogenase-deficient heterozygous female neonates. *Clin Chim Acta*. 2013;424:131–135.
- Minucci A, Giardina B, Zuppi C, Capoluongo E. Glucose-6-phosphate dehydrogenase laboratory assay: How, when, and why? *IUBMB Life*. 2009;61(1):27–34.
- G6PD/6PGD for the diagnosis of G6PD deficiency. Nurex diagnostics website. Accessed August 27, 2021.
- Roper D, Layton M, Rees D, et al. Laboratory diagnosis of G6PD deficiency. A British Society for Haematology Guideline. *Br J Haematol*. 2020;189(1):24–38.

- **Point of Care Device**
- https://baebies.com/products/finder/
- **A novel point-of-care device for measuring glucose-6-phosphate dehydrogenase enzyme deficiency** **https://doi.org/10.1016/j.semperi.2020.151356**

References

Case For Newborn Screening in the US, Slide 1

- Kaplan M, Wong RJ, Stevenson DK. Hemolysis and glucose-6-phosphate dehydrogenase deficiency-related neonatal hyperbilirubinemia. Neonatology. 2018;114(3):223–225.
- Bernardo J, Nock M. Pediatric provider insight into newborn screening for glucose-6-phosphate dehydrogenase deficiency. *Clin Pediatr (Phila)*. 2015;54(6):575–578.

Case for Newborn Screening in the US, Slide 2

- Watchko JF, Kaplan M, Stark AR, Stevenson DK, Bhutani VK. Should we screen newborns for glucose-6-phosphate dehydrogenase deficiency in the United States? *J Perinatol*. 2013;33(7):499–504.
- Nock ML, Johnson EM, Krugman RR, et al. Implementation and analysis of a pilot in-hospital newborn screening program for glucose-6-phosphate dehydrogenase deficiency in the United States. *J Perinatol*. 2011;31(2):112–117.
- Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF. Hyperbilirubinemia in the newborn infant > or =35 weeks' gestation: an update with clarifications. *Pediatrics*. 2009;124(4):1193–1198.

Case for Newborn Screening in the US, Slide 3

- Kaplan M, Hammerman C. Glucose-6-phosphate dehydrogenase deficiency: a hidden risk for kernicterus. *Semin Perinatol*. 2004;28(5):356–364.
- Joseph R, Ho LY, Gomez JM, Rajdurai VS, Sivasankaran S, Yip YY. Mass newborn screening for glucose-6-phosphate dehydrogenase deficiency in Singapore. *Southeast Asian J Trop Med Public Health*. 1999;30 Suppl 2:70–71.
- Vidavalur R, Bhutani VK. Economic evaluation of point of care universal newborn screening for glucose-6-Phosphate dehydrogenase deficiency in United States. *J Matern Fetal Neonatal Med*. Published online 2021:1–9.

Other References

- Up to Date: https://www.uptodate.com/contents/diagnosis-and-management-of-glucose-6-phosphate-dehydrogenase-g6pd-deficiency